These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1032 related articles for article (PubMed ID: 9667250)
1. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250 [TBL] [Abstract][Full Text] [Related]
2. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma. Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178 [TBL] [Abstract][Full Text] [Related]
3. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. Shipp MA; Neuberg D; Janicek M; Canellos GP; Shulman LN J Clin Oncol; 1995 Dec; 13(12):2916-23. PubMed ID: 8523055 [TBL] [Abstract][Full Text] [Related]
4. Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study. Gregory SA; Case DC; Bosserman L; Litwak DL; Berry WR; Kalman LA; Belt RJ; Saven A Clin Lymphoma; 2003 Sep; 4(2):93-8. PubMed ID: 14556680 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: a pilot study for a leukocyte count oriented regimen. Sawada KI; Sato N; Kohno M; Hannda H; Yasukouchi T; Tanngo M; Hirayama A; Koike T Leuk Lymphoma; 1995 Dec; 20(1-2):103-9. PubMed ID: 8750630 [TBL] [Abstract][Full Text] [Related]
6. A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin's lymphoma. Meyer RM; Gyger M; Langley R; Lespérance B; Caplan SN Leuk Lymphoma; 1998 Aug; 30(5-6):591-600. PubMed ID: 9711921 [TBL] [Abstract][Full Text] [Related]
7. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. Doorduijn JK; van der Holt B; van Imhoff GW; van der Hem KG; Kramer MH; van Oers MH; Ossenkoppele GJ; Schaafsma MR; Verdonck LF; Verhoef GE; Steijaert MM; Buijt I; Uyl-de Groot CA; van Agthoven M; Mulder AH; Sonneveld P J Clin Oncol; 2003 Aug; 21(16):3041-50. PubMed ID: 12915593 [TBL] [Abstract][Full Text] [Related]
8. CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: a dose-intensity analysis. Jacobson JO; Grossbard M; Shulman LN; Neuberg D Clin Lymphoma; 2000 Dec; 1(3):211-7; discussion 218. PubMed ID: 11707832 [TBL] [Abstract][Full Text] [Related]
9. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M; Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026 [TBL] [Abstract][Full Text] [Related]
10. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma. Tanosaki R; Okamoto S; Akatsuka N; Ishida A; Michikawa N; Masuda Y; Uchida H; Murata M; Kizaki M; Ikeda Y Cancer; 1994 Oct; 74(7):1939-44. PubMed ID: 7521788 [TBL] [Abstract][Full Text] [Related]
11. Delivery of full dose CHOP chemotherapy to elderly patients with aggressive non-Hodgkin's lymphoma without G-CSF support. Campbell C; Sawka C; Franssen E; Berinstein NL Leuk Lymphoma; 1999 Sep; 35(1-2):119-27. PubMed ID: 10512169 [TBL] [Abstract][Full Text] [Related]
12. Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients. Case DC; Desch CE; Kalman LA; Vongkovit P; Mena RR; Fridman M; Allen B Clin Lymphoma Myeloma; 2007 Mar; 7(5):354-60. PubMed ID: 17562245 [TBL] [Abstract][Full Text] [Related]
13. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461 [TBL] [Abstract][Full Text] [Related]
14. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates. Peters FP; Fickers MM; Erdkamp FL; Wals J; Wils JA; Schouten HC Ann Hematol; 2001 Jul; 80(7):406-10. PubMed ID: 11529466 [TBL] [Abstract][Full Text] [Related]
15. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505. Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K; Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359 [TBL] [Abstract][Full Text] [Related]
16. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group. Smith GM; Child JA; Cullen MH; Bailey NP; Woodruffe CM; Fletcher J; Earl H; Barnard D Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465 [TBL] [Abstract][Full Text] [Related]
17. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Morrison VA; Picozzi V; Scott S; Pohlman B; Dickman E; Lee M; Lawless G; Kerr R; Caggiano V; Delgado D; Fridman M; Ford J; Carter WB; Clin Lymphoma; 2001 Jun; 2(1):47-56. PubMed ID: 11707870 [TBL] [Abstract][Full Text] [Related]
18. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. Sonneveld P; de Ridder M; van der Lelie H; Nieuwenhuis K; Schouten H; Mulder A; van Reijswoud I; Hop W; Lowenberg B J Clin Oncol; 1995 Oct; 13(10):2530-9. PubMed ID: 7595704 [TBL] [Abstract][Full Text] [Related]
19. Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study. Chang JE; Seo S; Kim KM; Werndli JE; Bottner WA; Rodrigues GA; Sanchez FA; Saphner TJ; Longo WL; Kahl BS Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):379-84. PubMed ID: 21030351 [TBL] [Abstract][Full Text] [Related]
20. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. Kaplan LD; Kahn JO; Crowe S; Northfelt D; Neville P; Grossberg H; Abrams DI; Tracey J; Mills J; Volberding PA J Clin Oncol; 1991 Jun; 9(6):929-40. PubMed ID: 2033429 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]